Clinical effect of azithromycin in the treatment of mycoplasma pneumonia in children
小儿支原体肺炎应用阿奇霉素治疗的临床效果

摘要

目的 探究小儿支原体肺炎应用阿奇霉素治疗的临床效果。方法： 选取我院2020.12——2021.12期间收诊小儿支原体肺炎对象共计60例，按照平行对照分组法分出常规组、实验组，各30例。常规组应用红霉素治疗方案、实验组应用阿奇霉素治疗方案，整理治疗表现，比较两组临床治疗效果、症状改善指标、不良反应发生率、治疗前后炎性因子水平。结果 治疗前，两组对比炎性因子水平无差异性，P＞0.05。治疗后，相较常规组，实验组炎性因子水平、不良反应发生率更低，P＜0.05。相较常规组，实验组症状改善指标更优，P＜0.05。相较常规组，实验组临床治疗效果更高，P＜0.05。结论 小儿支原体肺炎疾病通过阿奇霉素治疗可抑制病理症状，消除炎性反应，用药安全建议推广。

Abstract

Objective To explore the clinical effect of azithromycin in the treatment of mycoplasma pneumonia in children. During the period of 2020, a total of 12 cases of children with mycoplasma pneumonia were divided into two groups: the first part and the second part.
Methods 2021 cases of children with mycoplasma pneumonia were divided into two groups. Among them, the first part of the subjects were included in the routine group treated with erythromycin, and the second part of the subjects were included in the experimental group treated with azithromycin. The treatment performance was sorted out, and the clinical treatment effect, symptom improvement index, incidence of adverse reactions and inflammatory factor level before and after treatment were compared between the two groups.
Results before treatment, there was no difference in the level of inflammatory factors between the two groups (P > 0.05). After treatment, the level of inflammatory factors and the incidence of adverse reactions in the experimental group were lower than those in the conventional group (P < 0.05). Compared with the routine group, the symptom improvement index of the experimental group was better (P < 0.05). Compared with the routine group, the clinical therapeutic effect of the experimental group was higher (P < 0.05).
Conclusion   Azithromycin can inhibit pathological symptoms and eliminate inflammatory reaction in children with mycoplasma pneumonia. It is suggested to popularize the safety of drug use.